The Studies Of BCMA-Fc As A Potential Drug

BLyS(B cell activating factor from the TNF family),a novel ligand of the tumornecrosis factor family. It exists both as a type II membrane protein and as a solubleprotein，which was found in1999and regulates B cell proliferation and survival.BCMA(B cell maturation antigen)is a recptor of Blys,which is a nonglycosylatedintegral membrane type I protein that is preferentially expressed in mature Blymphocytes.In the experimental research,we identified pET30a-BCMA-Fcrecombinant plasmid mainly and constructed a new recombinant plasmid(usingNdeⅠand XhoⅠ).Then pET30a-BCMA-Fc and pET28a-Fc recombinant plasmidswere induced by IPTG to express two kinds of corresponding fusionproteins.Subsequently,we have purified the fusion proteins using the protein A column.Last,we also analysed the specific binding capability of fusion proteins ofpET30a-BCMA-Fc and pET28a-Fc recombinant plasmids with BLyS and two specialsmall peptides.The main objective of study is further elaborating BLyS interactiingwith its receptors. Above all, this research may provide a experimental base for apromising treatment for B cell lymphoma and autoimmune diseases.So far, we successfully constructed a new recombinant plasmid pET28a-Fc and gothighly purified fusion protein.Foremostly we knew that the fusion proteins ofBCMA-Fc could bind with BAFF specificly, but the fusion proteins of Fc can’t bindwith BLyS by ELISA. Antagonizing peptide BC showed specific antagonizing effecton the binding of BLyS and BCMA-Fc and gradually increased with the increase ofconcentration of peptide.But the non-related peptide (NRP) displayed non-specificbinding.